Manulife at a Record High: Fair Priced, or Full of FOMO?

Manulife's Price Signals Confidence, Not Skepticism

At $44.77, Manulife sits just below the all-time high and well above its recent trading range. That does not guarantee the stock is expensive, but it does show that investors are no longer treating it like an ignored insurer. Recent results have built confidence, and confidence can attract momentum-driven buying just as often as it reflects fundamentals.

The operating case is hard to dismiss. In Q2, Manulife delivered core EPS of $1.09, core ROE of 16.3%, adjusted BVPS of $41.12 (up 15%), and adjusted EPS up 16%. Those are strong results for an insurer, and they help explain why the market has been willing to assign the stock a richer tone than it usually gives to traditional financials.

Still, a good company can still be a tougher buy after a strong run. Near record levels, part of the premium investors pay is psychological. The key question becomes whether execution can keep pace with a more optimistic narrative.

With the leadership handover already in view, the next few quarters should prove whether Manulife can sustain the standard of performance investors now expect.

Why the Multiple Has Room, but Less Room for Stretch

Manulife already looks like a mature earnings platform, so there is less reason for the market to award a fresh re-rating on the basis of improvement alone. Its earnings base is diversified across Canada at ~21% of earnings, Asia at ~38%, the US at ~16%, and wealth and asset management at ~25%. That mix is a strength during downturns, but it also makes the company harder to compress into a single peer group.

The quarter already proved part of the bull case

The latest results also narrowed the gap between story and proof. APE sales rose 21%, new business CSM increased 16%, and new business value rose 10%. That is exactly the kind of sequence that can persuade investors to pay a bit more today for earnings that may show up over time. It also means some of the optimism is already embedded near the all-time high area.

What would justify another multiple expansion?

If the multiple expands again, it will likely need one or more of the following:

• sustained follow-through from a business that already delivered core EPS of $1.09 and adjusted BVPS of $41.12
• cleaner visibility into how each segment contributes to earnings and capital
• evidence that Manulife can grow book and earnings ahead of the stock for a few quarters

For now, the path higher looks more execution-driven than multiple-driven.

The Real Debate: Quality Growth or a Higher Bar?

Strong results remove the discount, but they also raise expectations

The latest quarter did not create a new debate. It sharpened an existing one. With net income attributed to shareholders up 17%, strong core profitability, and healthy franchise metrics, Manulife has made the old bearish case harder to defend. At the same time, the market now has a higher bar for what counts as good enough.

The bull case rests on consistency

The bullish argument is straightforward: Manulife keeps delivering solid operating results across a diversified platform. When an insurer shows up quarter after quarter with strong profitability and sales momentum, it is reasonable for investors to assign it a better-than-average tone.

The bear case rests on what comes next

The more cautious view is not really about the last quarter. It is about valuation discipline. After a strong five-year run and a trip back near the all-time high, investors buying here have less margin for error if momentum cools or the next few prints are merely good rather than great.

That is why timing matters now. After a quarter that included a leadership handover already in view, the next few reports will show whether the market is paying for continued discipline or simply extrapolating the recent streak.

What Would Improve the Setup - and What Could Break It

A reset would not require business trouble

• A multiple reset: the market simply becomes less generous with the premium it assigns to consistency.
• An earnings catch-up: Manulife keeps compounding book and earnings so the current price starts to look reasonable in hindsight.

The US long-term care deal is a useful sentry test

One of the clearest new watchpoints is the CAD $3.2 billion risk transfer deal with Munich Re covering US long-term care products.

Bulls can read that as prudent capital management: lower tail risk and a cleaner earnings base. Bears may ask whether the need to transfer that risk openly says something less flattering about the original assumptions. The deal itself is not a problem, but how it affects future margins, capital flexibility, and earnings visibility matters.

What to watch next

Positive signs - Strong follow-through from the last quarterly results presentation, with sales and new-business momentum holding up - Evidence that risk transfer is making the business easier to model, not just smaller

Valuation-reset triggers - A broader market pullback that hits Manulife without a change in underlying execution - A pause in the recent sales and franchise momentum already established

Signals that would weaken the current narrative - The Munich Re deal starts to look expensive or reveals broader US long-term care stress - Management needs more balance-sheet support just as investors are being asked to pay up for continued compounding